Evidence map›Paper›PMID 22020161›Full record

ArticleAntiviral research2011

Novel plant-derived recombinant human interferons with broad spectrum antiviral activity.

Jeffrey W Koehler, Lesley C Dupuy, Aura R Garrison, Brett F Beitzel, Michelle J Richards, Daniel R Ripoll, Anders Wallqvist, Shia-Yen Teh, Andrew A Vaewhongs, Fakhrieh S Vojdani and 2 more

Open access · greenAbstract read
In one paragraph

Article in Antiviral research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Jeffrey W KoehlerU.S. Army Medical Research Institute of Infectious Diseases, Virology Division, Fort Detrick, MD 21702, USA.
Lesley C Dupuy
Aura R Garrison
Brett F Beitzel
Michelle J Richards
Daniel R Ripoll
Anders Wallqvist
Shia-Yen Teh
Andrew A Vaewhongs
Fakhrieh S Vojdani
Hal S Padgett
Connie S Schmaljohn
United States Army Medical Research Institute of Infectious Diseases · USNovici Biotech (United States) · USUnited States Army Medical Research and Development Command · USUniversity of California, Irvine · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Type I interferons (IFNs) are potent mediators of the innate immune response to viral infection. IFNs released from infected cells bind to a receptor (IFNAR) on neighboring cells, triggering signaling cascades that limit further infection. Subtle variations in amino acids can alter IFNAR binding and signaling outcomes. We used a new gene crossbreeding method to generate hybrid, type I human IFNs with enhanced antiviral activity against four dissimilar, highly pathogenic viruses. Approximately 1400 novel IFN genes were expressed in plants, and the resultant IFN proteins were screened for antiviral activity. Comparing the gene sequences of a final set of 12 potent IFNs to those of parent genes revealed strong selection pressures at numerous amino acids. Using three-dimensional models based on a recently solved experimental structure of IFN bound to IFNAR, we show that many but not all of the amino acids that were highly selected for are predicted to improve receptor binding.

Indexed as

Amino Acid SequenceAnimalsAntiviral AgentsChlorocebus aethiopsHumansInterferon Type IMicrobial Sensitivity TestsModels, MolecularMolecular Sequence DataNicotianaProtein ConformationRecombinant ProteinsSequence AlignmentVero CellsVirusesAntiviral AgentsInterferon Type IRecombinant Proteins

Identifiers

PMID22020161
PMCPMC9628711
OpenAlexW2126812092

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.